Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers

Neoplasma

Volumn 59, Issue 2, 2012, Pages 191-200

  Gumulec, J ^a,b,c   Masarik, M ^a,b,c   Krizkova, S ^b,c   Hlavna, M ^a   Babula, P ^b,c   Hrabec, R ^d   Rovny, A ^d   Masarikova, M ^b,c   Sochor, J ^b,c   Adam, V ^b,c   Eckschlager, T ^e   Kizek, R ^b,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^c BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Cancer; Electrochemistry; Immunodetection; mRNA1; Polymerase chain reaction; Tumor marker

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; PROSTATE SPECIFIC ANTIGEN; ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE; MESSENGER RNA; MT1A PROTEIN, HUMAN; MT2A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; ELECTROCHEMICAL DETECTION; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; ADENOCARCINOMA; CANCER GRADING; CASE CONTROL STUDY; COMPARATIVE STUDY; EVALUATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

ADENOCARCINOMA; ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; HUMANS; MALE; METALLOTHIONEIN; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84863819227     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_025     Document Type: Article

References (74)

1. FH SCHRODER, I VAN DER CRUIJSEN-KOETER, HJ DE KONING, AN VIS, RF HOEDEMAEKER et al. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806-811. http://dx.doi.org/10.1016/S0022-5347(05)67809-3
2. P JANTSCHEFF, N ESSER, A GEIPEL, P WOIAS, V ZIROLI et al. Metastasizing, Luciferase Transduced MATLu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug. Cancers 2011; 3: 2679-2695. http://dx.doi.org/10.3390/cancers3022679
3. G SARDANA, B DOWELL, EP DIAMANDIS. Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer. Clin Chem 2008; 54: 1951-1960. http://dx.doi.org/10.1373/clinchem.2008.110668
4. L COLLETTE, T BURZYKOWSKI, FH SCHRODER. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006; 42: 1344-1350. http://dx.doi. org/10.1016/j.ejca.2006.02.011
5. IP GARRAWAY, WY SUN, CP TRAN, S PERNER, B ZHANG et al. Human Prostate Sphere-Forming Cells Represent a Subset of Basal Epithelial Cells Capable of Glandular Regeneration In Vivo. Prostate 2010; 70: 491-501.
6. KL PENNEY, JA SINNOTT, K FALL, Y PAWITAN, Y HOSHIDA et al. mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. J Clin Oncol 2011; 29: 2391-2396. http://dx.doi.org/10.1200/JCO.2010.32.6421
7. A SBONER, F DEMICHELIS, S CALZA, Y PAWITAN, SR SETLUR et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010; 3: 8. http://dx.doi.org/10.1186/1755-8794-3-8
8. FH SCHROEDER, J HUGOSSON, MJ ROOBOL, TLJ TAMMELA, S CIATTO et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med 2009; 360: 1320-1328. http://dx.doi.org/10.1056/NEJMoa0810084
9. DV MAKAROV, S LOEB, RH GETZENBERG, AW PARTIN. Biomarkers for Prostate Cancer. Annu Rev Med 2009; 60: 139-151.
10. J TOSOIAN, S LOEB. PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer. The-ScientificWorldJOURNAL 2010; 10: 1919-1931. http://dx.doi. org/10.1100/tsw.2010.182
11. R RAAIJMAKERS, SH DE VRIES, BG BLIJENBERG, MF WILDHAGEN, R POSTMA et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol 2007; 52: 1358-1364. http://dx.doi.org/10.1016/j.eururo.2007.04.037
12. LG ZHANG, CY WANG, R YANG, JD SHI, R FU et al. Realtime quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol-Semin Orig Investig 2008; 26: 634-640. http://dx.doi. org/10.1016/j.urolonc.2007.07.016
13. MA ROWLANDS, D GUNNELL, R HARRIS, LJ VATTEN, JMP HOLLY et al. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int J Cancer 2009; 124: 2416-2429. http://dx.doi.org/10.1002/ijc.24202
14. SK BATABYAL, R MAJHI, RS BASU. Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer. Neoplasma 2009; 56: 68-71. http://dx.doi. org/10.4149/neo_2009_01_68
15. T JAMASPISHVILI, A SCORILAS, M KRAL, I KHOMERIKI, D KURFURSTOVA et al. Immunohistochemical localization and analysis of kallikrein-related peptidase 7 and 11 expression in paired cancer and benign foci in prostate cancer patients. Neoplasma 2011; 58: 298-303.
16. B DJAVAN, A KAZZAZI, L DULABON, M MARGREITER, A FARR et al. Diagnostic Strategies for Prostate Cancer. Eur Urol Suppl 2011; 10: E26-E37. http://dx.doi.org/10.1016/j.eursup.2011.03.010
17. T JAMASPISHVILI, M KRAL, I KHOMERIKI, V STUDENT, Z KOLAR et al. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 12-19. http://dx.doi.org/10.1038/pcan.2009.31
18. L HUMBERT, M CHEVRETTE Somatic Molecular Genetics of Prostate Cancer, in: W.D. Foulkes and K.A. Cooney (Eds.), Male Reproductive Cancers Epidemiology, Pathology and Genetics, Springer Verlag, New York, Dordrecht, Heidelberg, London, 2009.
19. S PUNNEN, RK NAM. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: A clinical conundrum in the PSA era. Surg Oncol-Oxf 2009; 18: 192-199. http://dx.doi.org/10.1016/j.suronc.2009.02.006
20. EI CANTO, KM SLAWIN. Early management of prostate cancer: How to respond to an elevated PSA? Annu Rev Med 2002; 53: 355-368.
21. S KRIZKOVA, M MASARIK, J KUKACKA, R PRUSA, T Eckschlager et al. Study of zinc-dependent aggregation of metallothionein from human prostatic cancer cell lines. EJC Suppl 2010; 8: 49-49. http://dx.doi.org/10.1016/S1359-6349(10)70993-9
22. S KRIZKOVA, M MASARIK, P MAJZLIK, J KUKACKA, J KRUSEOVA et al. Serum metallothionein in newly diagnosed patients with childhood solid tumors. Acta Biochim Pol 2010; 57: 561-566.
23. S KRIZKOVA, M RYVOLOVA, J GUMULEC, M MASARIK, V ADAM et al. Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker. Electrophoresis 2011; 32: 1952-1961. http://dx.doi.org/10.1002/elps.201000519
24. M MASARIK, N CERNEI, J GUMULEC, O ZITKA, P BABULA et al. Immunological determination of serum prostate specific antigen in cancer patients and tumor cell lines-New perspective. Int J Mol Med 2010; 26: S47-S47.
25. M MASARIK, N CERNEI, P MAJZLIK, D HUSKA, H BINKOVA et al. Level of metallothionein, glutathione and heat-stable proteins in tumors from patients with head and neck cancer. Int J Mol Med 2010; 26: S46-S46.
26. M MASARIK, J GUMULEC, S KUCHTICKOVA, V ADAM, S KRIZKOVA et al. Detection of metallothionein and alpha-methylacyl CoA racemase as potential new markers for prostate carcinoma. Int J Mol Med 2009; 24: S48-S48.
27. M MASARIK, J GUMULEC, S KUCHTICKOVA, V KUDLACKOVA, N CERNEI et al. Determination of metallothioneins and alpha-methylacyl-CoA racemase in patients with prostate carcinoma. Int J Mol Med 2010; 26: S47-S47.
28. M MASARIK, J GUMULEC, S KUCHTICKOVA, V KUDLACKOVA, M JURAJDA et al. Determination of novel tumor markers in prostate carcinoma. FEBS J 2010; 277: 188-188.
29. M MASARIK, J GUMULEE, N CERNEI, O ZITKA, P BABULA et al. Sarcosine as a new marker for prostate tumors. Int J Mol Med 2010; 26: S47-S47.
30. ME MCDOWELL, S OCCHIPINTI, RA GARDINER, PD BAADE, SK STEGINGA. A review of prostate-specific antigen screening prevalence and risk perceptions for firstdegree relatives of men with prostate cancer. Eur J Cancer Care 2009; 18: 545-555. http://dx.doi.org/10.1111/j.1365-2354.2008.01046.x
31. J PETRLOVA, D POTESIL, R MIKELOVA, O BLASTIK, V ADAM et al. Attomole voltammetric determination of metallothionein. Electrochim Acta 2006; 51: 5112-5119. http://dx.doi.org/10.1016/j.electacta.2006.03.078
32. R KIZEK, L TRNKOVA, E PALECEK. Determination of metallothionein at the femtomole level by constant current stripping chronopotentiometry. Anal Chem 2001; 73: 4801-4807. http://dx.doi.org/10.1021/ac010126u
33. V ADAM, I FABRIK, T ECKSCHLAGER, M STIBOROVA, L TRNKOVA et al. Vertebrate metallothioneins as target molecules for analytical techniques. TRAC-Trends Anal Chem 2010; 29: 409-418. http://dx.doi.org/10.1016/j.trac.2010.02.004
34. T ECKSCHLAGER, V ADAM, J HRABETA, K FIGOVA, R KIZEK. Metallothioneins and Cancer. Curr Protein Pept Sci 2009; 10: 360-375. http://dx.doi.org/10.2174/138920309788922243
35. S KRIZKOVA, V ADAM, T ECKSCHLAGER, R KIZEK. Using of chicken antibodies for metallothionein detection in human blood serum and cadmium-treated tumor cell lines after dot-and electroblotting. Electrophoresis 2009; 30: 3726-3735. http://dx.doi.org/10.1002/elps.200900201
36. S KRIZKOVA, I FABRIK, V ADAM, P HRABETA, T Eckschlager et al. Metallothionein-a promising tool for cancer diagnostics. Bratisl Med J 2009; 110: 93-97.
37. R KUEFER, S VARAMBALLY, M ZHOU, PC LUCAS, M LOEFFLER et al. alpha-Methyl acyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002; 161: 841-848. http://dx.doi. org/10.1016/S0002-9440(10)64244-7
38. J LUO, S ZHA, WR GAGE, TA DUNN, JL HICKS et al. alpha-Methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220-2226.
39. JC XU, JA STOLK, XQ ZHANG, SJ SILVA, RL HOUGHTON et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000; 60: 1677-1682.
40. AJ EVANS. alpha-Methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 2003; 56: 892-897. http://dx.doi.org/10.1136/jcp.56.12.892
41. MA RUBIN, M ZHOU, SM DHANASEKARAN, S VARAMBALLY, TR BARRETTE et al. alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA-J Am Med Assoc 2002; 287: 1662-1670.
42. RM SRAMKOSKI, TG PRETLOW, JM GIACONIA, TP PRETLOW, S SCHWARTZ et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol-Anim 1999; 35: 403-409.
43. V ADAM, J PETRLOVA, J WANG, T ECKSCHLAGER, L TRNKOVA et al. Zeptomole Electrochemical Detection of Metallothioneins. PLoS One 2010; 5.
44. V ADAM, O BLASTIK, S KRIZKOVA, P LUBAL, J KUKACKA et al. Application of the Brdicka reaction in determination of metallothionein in patients with tumors. Chem Listy 2008; 102: 51-58.
45. Y OGRA, KT SUZUKI. Targeting of tetrathiomolybdate on the copper accumulating in the liver of LEC rats. J Inorg Biochem 1998; 70: 49-55. http://dx.doi.org/10.1016/S0162-0134(98)00012-9
46. M KATO, W LIU, AA AKHAND, Y DAI, M OHBAYASHI et al. Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I ret transgenic mouse lines. Oncogene 1999; 18: 837-842. http://dx.doi.org/10.1038/sj.onc.1202329
47. I NAKAGAWA, M SUZUKI, N IMURA, A NAGANUMA. Involvement of oxidative stress in paraquat-induced metallothionein synthesis under glutathione depletion. Free Radic Biol Med 1998; 24: 1390-1395. http://dx.doi.org/10.1016/S0891-5849(98)00008-2
48. K SUZUKI, K NAKAZATO, K NAKAJIMA Cadmium-induced metallothionein expression and metallothionein mRNA in mice, 1999.
49. Y SUZUKI, Y KONDO, S HIMENO, K NEMOTO, M AKIMOTO et al. Role of antioxidant systems in human androgen-independent prostate cancer cells. Prostate 2000; 43: 144-149. http://dx.doi.org/10.1002/(SICI)1097-0045(20000501)43:2<144::AID-PROS9>3.0.CO;2-H
50. K TAKABA, K SAEKI, K SUZUKI, H WANIBUCHI, S FUKUSHIMA. Significant overexpression of metallothionein and cyclin D1 and apoptosis in the early process of rat urinary bladder carcinogenesis induced by treatment with N-butyl-N-(4-hydroxybutyl)nitrosamine or sodium L-ascorbate. Carcinogenesis 2000; 21: 691-700. http://dx.doi.org/10.1093/carcin/21.4.691
51. BX ZHANG, M SATOH, N NISHIMURA, JS SUZUKI, H SONE et al. Metallothionein deficiency promotes mouse skin carcinogenesis induced by 7,12-dimethylbenz a anthracene. Cancer Res 1998; 58: 4044-4046.
52. C TOHYAMA, N NISHIMURA, JS SUZUKI, M KARASAWA, H NISHIMURA. Metallothionein messenger-rna in the testis and prostate of the rat detected by digoxigenin-labeled riboprobe. Histochemistry 1994; 101: 341-346. http://dx.doi. org/10.1007/BF00268995
53. S KOIZUMI, K SUZUKI, F OTSUKA. A nuclear factor that recognizes the metal-responsive elements of human metallothionein-iia gene. J Biol Chem 1992; 267: 18659-18664.
54. AL ALBRECHT, RK SINGH, S SOMJI, MA SENS, DA SENS et al. Basal and metal-induced expression of metallothionein isoform 1 and 2 genes in the RWPE-1 human prostate epithelial cell line. J Appl Toxicol 2008; 28: 283-293. http://dx.doi. org/10.1002/jat.1277
55. H WEI, MM DESOUKI, S LIN, D XIAO, RB FRANKLIN et al. Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 2008; 7: 1-7. http://dx.doi.org/10.1186/1476-4598-7-7
56. M YAMASAKI, T NOMURA, F SATO, H MIMATA. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 2007; 18: 1145-1153.
57. T SUZUKI, H YAMANAKA, Y TAMURA, K NAKAJIMA, K KANATANI et al. Metallothionein of prostatic tissues and fluids in rats and humans. Tohoku J Exp Med 1992; 166: 251-257. http://dx.doi.org/10.1620/tjem.166.251
58. YC WONG, YZ WANG, JSK LEE, NNC TAM, D LEE. Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the Noble rat. Tumor Biol 2000; 21: 328-336. http://dx.doi.org/10.1159/000030138
59. JD LEE, SM WU, LY LU, YT YANG, SY JENG. Cadmium Concentration and Metallothionein Expression in Prostate Cancer and Benign Prostatic Hyperplasia of Humans. J Formos Med Assoc 2009; 108: 554-559. http://dx.doi.org/10.1016/S0929-6646(09)60373-9
60. J SCHOPFER, G DRASCH, GN SCHRAUZER. Selenium and Cadmium Levels and Ratios in Prostates, Livers, and Kidneys of Nonsmokers and Smokers. Biol Trace Elem Res 2010; 134: 180-187. http://dx.doi.org/10.1007/s12011-010-8636-y
61. P ATHANASSIADOU, A BANTIS, M GONIDI, P ATHANASSIADES, E AGELONIDOU et al. The expression of metallothioneins on imprint smears of prostate carcinoma: Correlation with clinicopathologic parameters and tumor proliferative capacity. Tumori 2007; 93: 189-194.
62. Z JIANG, BA WODA. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol 2004; 11: 316-321. http://dx.doi.org/10.1097/01. pap.0000146924.14246.be
63. C XIE, HJ KIM, JG HAW, A KALBASI, BK GARDNER et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med 2011; 9.
64. JL WRIGHT, ML NEUHOUSER, DW LIN, EM KWON, ZD FENG et al. AMACR Polymorphisms, Dietary Intake of Red Meat and Dairy and Prostate Cancer Risk. Prostate 2011; 71: 498-506. http://dx.doi.org/10.1002/pros.21267
65. XJ WU, M ZAYZAFOON, XZ ZHANG, O HAMEED. Is There a Role for Fatty Acid Synthase in the Diagnosis of Prostatic Adenocarcinoma? A Comparison With AMACR. Am J Clin Pathol 2011; 136: 239-246. http://dx.doi.org/10.1309/AJCP0Y5QWWYDKCJE
66. V ADAM, J BALOUN, I FABRIK, L TRNKOVA, R KIZEK. An electrochemical detection of metallothioneins at the zeptomole level in nanolitre volumes. Sensors 2008; 8: 2293-2305. http://dx.doi.org/10.3390/s8042293
67. I FABRIK, S KRIZKOVA, D HUSKA, V ADAM, J HUBALEK et al. Employment of electrochemical techniques for metallothionein determination in tumor cell lines and patients with a tumor disease. Electroanalysis 2008; 20: 1521-1532. http://dx.doi.org/10.1002/elan.200704215
68. S KRIZKOVA, I FABRIK, V ADAM, J KUKACKA, R PRUSA et al. Utilizing of adsorptive transfer stripping technique Brdicka reaction for determination of metallothioneins level in melanoma cells, blood serum and tissues. Sensors 2008; 8: 3106-3122. http://dx.doi.org/10.3390/s8053106
69. S KRIZKOVA, I FABRIK, V ADAM, J KUKACKA, R PRUSA et al. Effects of reduced glutathione, surface active agents and ionic strength on the detection of metallothioneins by using of Brdicka reaction. Electroanalysis 2009; 21: 640-644. http://dx.doi.org/10.1002/elan.200804406
70. RA GOYER, J LIU, MP WAALKES. Cadmium and cancer of prostate and testis. Biometals 2004; 17: 555-558. http://dx.doi. org/10.1023/B:BIOM.0000045738.59708.20
71. MO PEDERSEN, A LARSEN, M STOLTENBERG, M PENKOWA. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 2009; 44: 29-64.
72. OJK TAN, BH BAY, VTK CHOW. Differential expression of metallothionein isoforms in nasopharyneal cancer and inhibition of cell growth by antisense down-regulation of metallothionein-2A. Oncol Rep 2005; 13: 127-131.
73. B WERYNSKA, B PULA, B MUSZCZYNSKA-BERNHARD, A PIOTROWSKA, A JETHON et al. Correlation between Expression of Metallothionein and Expression of Ki-67 and MCM-2 Proliferation Markers in Non-Small Cell Lung Cancer. Anticancer Res 2011; 31: 2833-2839.
74. D LAUKENS, A WAEYTENS, P DE BLESER, C CUVELIER, M DE VOS. Human Metallothionein Expression under Normal and Pathological Conditions: Mechanisms of Gene Regulation Based on In silico Promoter Analysis. Crit Rev Eukaryot Gene Expr 2009; 19: 301-317.